Efficacy and Safety of Influenza Vaccine During Sarcoidosis
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Sarcoidosis is an inflammatory disease of unknown origin that can affect all organs,
especially the lungs and mediastinum. Some location of sarcoidosis may require treatment with
corticosteroids or immunosuppressors.Although seasonal influenza vaccination can be
recommended in sarcoidosis in some subgroups at risk (respiratory failure, pulmonary
fibrosis, age over 65, use of immunosuppressive therapy, etc ...), the investigators
presently have no data on the efficacy and safety (absence of adverse reactions) of seasonal
influenza vaccination in sarcoidosis.Especially it is not known whether the seasonal
influenza vaccine provides the same rate and same type of vaccine response in sarcoidosis
patients than in the general population. Similarly, it is unclear whether the vaccine
response is modified by the severity of the disease and treatment with corticosteroids and
immunosuppressors.Based on what is known in systemic lupus and rheumatoid arthritis, which
are both inflammatory and autoimmune diseases, the investigators expect at best a 50% vaccine
response in patients with sarcoidosis and a 85% vaccination response in healthy controls. The
demonstration of a vaccine response could allow reconsidering new vaccine approaches in
sarcoidosis.